Attention Deficit Hyperactivity Disorder (ADHD) Prediction of Treatment Response



Status:Recruiting
Conditions:Neurology, Psychiatric
Therapuetic Areas:Neurology, Psychiatry / Psychology
Healthy:No
Age Range:18 - 55
Updated:8/9/2018
Start Date:July 1, 2018
End Date:December 1, 2020
Contact:Elizabeth Noyes
Email:enoyes@partners.org
Phone:617-724-2551

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria
This is a 6-month open-label, randomized control trial in adults to find out if certain
neuromarkers can predict individual treatment response to stimulant medications for Attention
Deficit Hyperactivity Disorder (ADHD). Males and females, ages 18-55, will be randomized to
receive either an amphetamine or a methylphenidate formulation for their ADHD. Before
beginning to receive medication treatment, each subject will complete an MRI scan at MIT.


Inclusion Criteria:

- Male and female adults ages 18-55

- A diagnosis of DSM-V ADHD based on clinical assessment supported by the ADHD module of
a structured diagnostic interview

- Proficiency in English

- Right-handed

Exclusion Criteria:

- Any contraindication for the use of a stimulant medication

- Investigator and his/her immediate family (spouse, parent, child, grandparent, or
grandchild)

- Any contraindications for MRI examination (metallic implants, such as pacemakers,
surgical aneurysm clips, or known metal fragments in the body)

- Women who are currently pregnant or breastfeeding, as confirmed by a urine pregnancy
test

- Clinically significant abnormal baseline laboratory values, including systolic and
diastolic blood pressure parameters above 140 and 90, respectively and resting heart
rate outside 60-100 bpm
We found this trial at
1
site
Massachusetts General Hospital
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
Principal Investigator: Joseph Biederman, MD
Phone: 617-724-2511
?
mi
from
Boston, MA
Click here to add this to my saved trials